FDA Calls for Restrictions on Ovarian Cancer Drug Rubraca Due to High Mortality Rates
If the drug maker Clovis does not update the Rubraca label, the FDA may seek third party recommendations on whether to remove Rubraca from the market
If the drug maker Clovis does not update the Rubraca label, the FDA may seek third party recommendations on whether to remove Rubraca from the market